Gilead Sciences
Belgo-Dutch biotech Galapagos NV
AbbVie
Amgen
Novo Nordisk
CO
the U.S. Food and Drug Administration
RBC
Barclays, Centerview Partners
Lazard
Moelis & Co
Morgan Stanley
Shubham Kalia
Reuters
All Rights Reserved
Daniel O’Day
Sanofi
Brian Abrahams
Ismail Shakil
Phil Blenkinsop
John Miller
Georgina Prodhan
David EvansAll
Belgian
French
European
Galapagos
Europe
No matching tags
U.S.
Pfizer
O’Day
Belgium
Ablynx
Bengaluru
Brussels
Zurich
London
No matching tags
Galapagos’s most advanced drug in development is filgotinib, an experimental compound being advanced for rheumatoid arthritis and inflammatory bowel disease that Gilead intends to submit to the U.S. Food and Drug Administration this year. The two companies first partnered four years ago to develop a drug targeting inflammatory diseases, with Gilead paying more than $2 billion for the development of filgotinib, as well as an equity stake in the European firm.
As said here by Reuters Editorial